OS Therapies Incorporated carries a market capitalization of 69.48M, placing it among publicly traded companies globally. Its enterprise value stands at 45.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 69.48M |
| Enterprise Value | 45.43M |
OS Therapies Incorporated currently has 39.28M shares outstanding.
| Shares Outstanding | 39.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.58 |
| P/TBV Ratio | -2.62 |
| P/FCF Ratio | -2.99 |
| P/OCF Ratio | -2.93 |
OS Therapies Incorporated maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.41, indicating conservative leverage, while an interest coverage ratio of -443.13 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.05 |
| Quick Ratio | 0.05 |
| Debt / Equity | -12.41 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | -443.13 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -610.85 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
OS Therapies Incorporated's stock has declined approximately -14.28571% over the past 52 weeks. The 50-day moving average sits at 1.76, while the 200-day moving average is 1.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | -14.28571% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 1.63 |
| Average Volume (20 Days) | N/A |
EBITDA reached -33.39M, while operating income came in at -33.87M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -33.87M |
| Pretax Income | -35.27M |
| Net Income | -35.27M |
| EBITDA | -33.39M |
| EBIT | -33.87M |
| Earnings Per Share (EPS) | -1.11 |
OS Therapies Incorporated holds 917,552.00 in cash and equivalents against 1.34M in total debt, resulting in a net debt position of 425,390.00. Total book value stands at -77.54M, with working capital of -16.04M providing operational flexibility.
| Cash & Cash Equivalents | 917,552.00 |
| Total Debt | 1.34M |
| Net Debt | 425,390.00 |
| Equity (Book Value) | -77.54M |
| Book Value Per Share | -2.43 |
| Working Capital | -16.04M |
OS Therapies Incorporated produced -15.36M in operating cash flow over the past twelve months. After subtracting -316,423.00 in capital expenditures, free cash flow totaled -15.68M - equivalent to -0.49 per share.
| Operating Cash Flow | -15.36M |
| Capital Expenditures | -316,423.00 |
| Free Cash Flow | -15.68M |
| FCF Per Share | -0.49 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -30.22 |
| FCF Yield | -33.43 |
OS Therapies Incorporated posts an Altman Z-Score of -259.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -259.18 |